Ronald van Vollenhoven, ACR 2020 – Ustekinumab in the Treatment of Systemic Lupus Erythematosus

We caught up with Ronald van Vollenhoven (Amsterdam University Medical Centers, Amsterdam, the Netherlands) to discuss the use of ustekinumab in patients with active systemic lupus erythematosus (Clinical Trial Identifier: NCT02349061). The abstract ‘Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study’ (ABSTRACT NUMBER: 1826) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.

Questions

1. What is the rationale for the use of ustekinumab in the treatment of systemic lupus erythematosus (SLE)? (0:26)
2. Could you tell us a little about the Phase 2 study you are presenting, and its findings? (1:31)
3. What are the challenges in selecting clinical endpoints for SLE studies? (3:15)
4. What were the strengths and limitations of this study? (4:28)
5. How will these findings inform future research? (5:50)

Disclosures: Research Support (institutional grants): BMS, GSK, Lilly, UCB. Support for Educational programs (institutional grants): Pfizer, Roche. Consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB. Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).